iBio (IBIO) Expected to Release Quarterly Earnings on Friday

Key Points

• iBio is expected to report Q4 2026 earnings before the market opens Friday, September 4. Analysts anticipate a loss of $0.07 per share and revenue of approximately $80,000.
• IBIO opened at $1.40, below its 50-day average of $1.49 and 200-day average of $1.84. The stock has traded between $0.77 and $3.82 over the past year, with a market capitalization of about $69.6 million.
• Analyst sentiment is broadly positive, with an average “Buy” rating and a $5.00 price target, although one research firm has issued a sell rating. Institutional investors own approximately 7.9% of the company.

iBio (NASDAQ:IBIO - Get Free Report) is expected to be posting its Q4 2026 results before the market opens on Friday, September 4th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $0.08 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Friday, September 25, 2026 at 4:00 PM ET.

iBio Stock Performance

IBIO stock opened at $1.40 on Friday. The company's fifty day moving average price is $1.49 and its 200-day moving average price is $1.84. iBio has a one year low of $0.77 and a one year high of $3.82. The company has a market capitalization of $69.55 million, a PE ratio of -2.41 and a beta of 1.30.

Hedge Funds Weigh In On iBio

A number of institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of iBio during the 4th quarter valued at approximately $71,000. Persistent Asset Partners Ltd bought a new stake in iBio in the fourth quarter worth $76,000. Susquehanna International Group LLP purchased a new position in iBio during the third quarter worth $37,000. Cubist Systematic Strategies LLC purchased a new position in iBio during the first quarter worth $224,000. Finally, State Street Corp increased its position in iBio by 116.3% during the fourth quarter. State Street Corp now owns 72,899 shares of the company's stock valued at $141,000 after acquiring an additional 39,200 shares during the last quarter. Hedge funds and other institutional investors own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on IBIO shares. B. Riley Financial assumed coverage on shares of iBio in a report on Friday, June 5th. They issued a "buy" rating and a $6.00 price target on the stock. Chardan Capital reissued a "buy" rating and set a $5.00 price objective on shares of iBio in a report on Thursday, July 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of iBio in a report on Wednesday, June 24th. Raymond James Financial started coverage on iBio in a research report on Monday, June 8th. They set an "outperform" rating and a $5.00 price objective for the company. Finally, Wall Street Zen cut iBio from a "hold" rating to a "sell" rating in a report on Sunday, August 23rd. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $5.00.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source